Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

NCT04819347 ↗

Phase 2 Unknown 24 enrolled Frontier Biotechnologies Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 2 study to evaluate the safety and tolerability of combination therapy with Albuvirtide (ABT) and 3BNC117 in virologically suppressed subjects with HIV-1 infection and explore the potential of viral suppression and viral reservoir clearance after analytical treatment interruption (ATI).

Timeline

Start: 2021-05-01
Primary completion: 2022-06-01
Completion: 2022-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Albuvirtide	Other / unclassified	0.32 g	Intravenous
Subject	LAFUVITUG	Monoclonal antibody	2 g	Intravenous

Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

Summary

Timeline

Drugs

Indications